An Implantable Smart Chip to Treat Chronic Pain

Tuesday, February 14, 2012 - 6:30pm

In Canada, the cost of chronic pain to the healthcare system surpasses that of cancer, heart disease and HIV combined. Direct healthcare costs due to chronic pain exceed $6 billion per year and these costs are expected to escalate to over $10 billion per year. Chronic pain is pain that extends beyond the expected period of healing. It affects 1 in 5 Canadians with prevalence increasing with age. Currently, treatment is most popularly limited to non-steroidal anti-inflammatory drugs (NSAIDs) and opioids. Although effective, these forms of treatment are only beneficial to patients suffering from mild to moderate levels of pain. One emerging advanced pain therapy involves Spinal Cord Stimulation (SCS). SCS is a treatment involving the use of a neurostimulator to apply electrical current to the dorsal column of the spinal cord. The stimulation interrupts the feeling of pain and substitutes it with a tingling sensation known as "parasthesia". Although these treatments have shown to be effective for stronger levels of chronic pain, there have been significant cases of adverse events due to functionality, implantation, and biocompatibility. Also, the presence of adverse events and increases in cost and complexity for implantation has deterred physicians from opting into such treatment methods.

Ingenia Healthcare Solutions will outline a technological advance towards SCS devices based on Saluda Medical’s INS2 smart chip stimulator and highlight the steps needed for this new generation of devices to alter physician treatment behaviour and potentially increase the market penetration of SCS devices within the larger Chronic Pain domain. 

team Ingenia

Presented by Team Ingenia.

Tuesday, February 14, 2012, 6:30-7:30pm, Instructional Centre, Room 335. Also available via webcast. Open to the public.

The Master of Biotechnology Program would like to thank AstraZeneca Canada Inc. for their continued support of this seminar series.